MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.
Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...
A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending ...
The 5977A MSD includes a new, highly sensitive Extractor Ion Source for higher Signal-to-Noise (SNR) and a statistically based, low-femtogram Instrument Detection Limit (IDL). Skip to content Menu ...
This page features the latest news about the Merck & Co DRC stock. Merck’s Keytruda Meets Primary Endpoints, FDA Review Scheduled for October 16 Merck & Co.'s immunotherapy drug, Keytruda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback